{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T20:09:30Z","timestamp":1762459770618,"version":"3.40.3"},"publisher-location":"Cham","reference-count":43,"publisher":"Springer International Publishing","isbn-type":[{"type":"print","value":"9783030504939"},{"type":"electronic","value":"9783030504946"}],"license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019]]},"DOI":"10.1007\/164_2019_256","type":"book-chapter","created":{"date-parts":[[2019,8,2]],"date-time":"2019-08-02T11:17:40Z","timestamp":1564744660000},"page":"25-37","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Pharmacotherapy of Duchenne Muscular Dystrophy"],"prefix":"10.1007","author":[{"given":"Eric P.","family":"Hoffman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,8,3]]},"reference":[{"key":"256_CR1","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.jns.2017.12.024","volume":"386","author":"K Adachi","year":"2018","unstructured":"Adachi K, Hashiguchi S, Saito M, Kashiwagi S, Miyazaki T, Kawai H, Yamada H, Iwase T, Akaike M, Takao S, Kobayashi M, Ishizaki M, Matsumura T, Mori-Yoshimura M, Kimura E (2018) Detection and management of cardiomyopathy in female dystrophinopathy carriers. J Neurol Sci 386:74\u201380","journal-title":"J Neurol Sci"},{"issue":"6410","key":"256_CR2","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1126\/science.aau1549","volume":"362","author":"L Amoasii","year":"2018","unstructured":"Amoasii L, Hildyard JCW, Li H, Sanchez-Ortiz E, Mireault A, Caballero D, Harron R, Stathopoulou TR, Massey C, Shelton JM, Bassel-Duby R, Piercy RJ, Olson EN (2018) Gene editing restores dystrophin expression in a canine model of Duchenne muscular dystrophy. Science 362(6410):86\u201391","journal-title":"Science"},{"key":"256_CR3","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1212\/WNL.41.9.1491","volume":"41","author":"E Arikawa","year":"1991","unstructured":"Arikawa E, Hoffman EP, Kaido M, Nonaka I, Sugita H, Arahata K (1991) The frequency of patients having dystrophin abnormalities in a limb-girdle patient population. Neurology 41:1491\u20131496","journal-title":"Neurology"},{"issue":"12","key":"256_CR4","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1212\/WNL.0000000000001950","volume":"85","author":"L Bello","year":"2015","unstructured":"Bello L, Gordish-Dressman H, Morgenroth LP, Henricson EK, Duong T, Hoffman EP, Cnaan A, McDonald CM, Investigators CINRG (2015) Prednisone\/prednisolone and deflazacort regimens in the CINRG Duchenne natural history study. Neurology 85(12):1048\u20131055","journal-title":"Neurology"},{"issue":"10","key":"256_CR5","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.nmd.2016.07.002","volume":"26","author":"P Bettica","year":"2016","unstructured":"Bettica P, Petrini S, D'Oria V, D'Amico A, Catteruccia M, Pane M, Sivo S, Magri F, Brajkovic S, Messina S, Vita GL, Gatti B, Moggio M, Puri PL, Rocchetti M, de Nicolao G, Vita G, Comi GP, Bertini E, Mercuri E (2016) Histological effects of givinostat in boys with Duchenne muscular dystrophy. Neuromuscul Disord 26(10):643\u2013649","journal-title":"Neuromuscul Disord"},{"issue":"24","key":"256_CR6","doi-asserted-by":"publisher","first-page":"e2146","DOI":"10.1212\/WNL.0000000000005680","volume":"90","author":"JS Charleston","year":"2018","unstructured":"Charleston JS, Schnell FJ, Dworzak J, Donoghue C, Lewis S, Chen L, Young GD, Milici AJ, Voss J, DeAlwis U, Wentworth B, Rodino-Klapac LR, Sahenk Z, Frank D, Mendell JR (2018) Eteplirsen treatment for Duchenne muscular dystrophy: exon skipping and dystrophin production. Neurology 90(24):e2146\u2013e2154","journal-title":"Neurology"},{"issue":"6","key":"256_CR7","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1212\/01.wnl.0000173836.09176.c4","volume":"65","author":"YW Chen","year":"2005","unstructured":"Chen YW, Nagaraju K, Bakay M, McIntyre O, Rawat R, Shi R, Hoffman EP (2005) Early onset of inflammation and later involvement of TGFbeta in Duchenne muscular dystrophy. Neurology 65(6):826\u2013834","journal-title":"Neurology"},{"key":"256_CR8","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.phrs.2018.09.007","volume":"136","author":"LS Conklin","year":"2018","unstructured":"Conklin LS, Damsker JM, Hoffman EP, Jusko WJ, Mavroudis PD, Schwartz BD, Mengle-Gaw LJ, Smith EC, Mah JK, Guglieri M, Nevo Y, Kuntz N, McDonald CM, Tulinius M, Ryan MM, Webster R, Castro D, Finkel RS, Smith AL, Morgenroth LP, Arrieta A, Shimony M, Jaros M, Shale P, McCall JM, Hathout Y, Nagaraju K, van den Anker J, Ward LM, Ahmet A, Cornish MR, Clemens PR (2018) Phase IIa trial in Duchenne muscular dystrophy shows vamorolone is a first-in-class dissociative steroidal anti-inflammatory drug. Pharmacol Res 136:140\u2013150","journal-title":"Pharmacol Res"},{"issue":"6","key":"256_CR9","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1002\/mus.26441","volume":"59","author":"AM Connolly","year":"2019","unstructured":"Connolly AM, Zaidman CM, Golumbek PT, Cradock MM, Flanigan KM, Kuntz NL, Finkel RS, McDonald CM, Iannaccone ST, Anand P, Siener CA, Florence JM, Lowes LP, Alfano LN, Johnson LB, Nicorici A, Nelson LL, Mendell JR, MDA DMD Clinical Research Network (2019) Twice-weekly glucocorticosteroids in infants and young boys with Duchenne muscular dystrophy. Muscle Nerve 59(6):650\u2013657","journal-title":"Muscle Nerve"},{"issue":"1","key":"256_CR10","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s12883-019-1304-8","volume":"19","author":"L Cowen","year":"2019","unstructured":"Cowen L, Mancini M, Martin A, Lucas A, Donovan JM (2019) Variability and trends in corticosteroid use by male United States participants with Duchenne muscular dystrophy in the Duchenne registry. BMC Neurol 19(1):84","journal-title":"BMC Neurol"},{"issue":"2","key":"256_CR12","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.ajpath.2012.10.018","volume":"182","author":"OM Dorchies","year":"2013","unstructured":"Dorchies OM, Reutenauer-Patte J, Dahmane E, Ismail HM, Petermann O, Patthey-Vuadens O, Comyn SA, Gayi E, Piacenza T, Handa RJ, D\u00e9costerd LA, Ruegg UT (2013) The anticancer drug tamoxifen counteracts the pathology in a mouse model of duchenne muscular dystrophy. Am J Pathol 182(2):485\u2013504","journal-title":"Am J Pathol"},{"issue":"1","key":"256_CR13","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3233\/JND-180341","volume":"6","author":"E Finanger","year":"2019","unstructured":"Finanger E, Vandenborne K, Finkel RS, Lee Sweeney H, Tennekoon G, Yum S, Mancini M, Bista P, Nichols A, Liu H, Fretzen A, Donovan JM (2019) Phase 1 study of edasalonexent (CAT-1004), an oral NF-\u03baB inhibitor, in pediatric patients with Duchenne muscular dystrophy. J Neuromuscul Dis 6(1):43\u201354","journal-title":"J Neuromuscul Dis"},{"issue":"10","key":"256_CR14","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.1016\/j.celrep.2015.07.066","volume":"12","author":"AA Fiorillo","year":"2015","unstructured":"Fiorillo AA, Heier CR, Novak JS, Tully CB, Brown KJ, Uaesoontrachoon K, Vila MC, Ngheim PP, Bello L, Kornegay JN, Angelini C, Partridge TA, Nagaraju K, Hoffman EP (2015) TNF-\u03b1-induced microRNAs control dystrophin expression in Becker muscular dystrophy. Cell Rep 12(10):1678\u20131690","journal-title":"Cell Rep"},{"issue":"9","key":"256_CR15","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1152\/physiolgenomics.00134.2017","volume":"50","author":"AA Fiorillo","year":"2018","unstructured":"Fiorillo AA, Tully CB, Damsker JM, Nagaraju K, Hoffman EP, Heier CR (2018) Muscle miRNAome shows suppression of chronic inflammatory miRNAs with both prednisone and vamorolone. Physiol Genomics 50(9):735\u2013745","journal-title":"Physiol Genomics"},{"issue":"1","key":"256_CR16","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1002\/mus.23831","volume":"48","author":"RC Griggs","year":"2013","unstructured":"Griggs RC, Herr BE, Reha A, Elfring G, Atkinson L, Cwik V, McColl E, Tawil R, Pandya S, McDermott MP, Bushby K (2013) Corticosteroids in Duchenne muscular dystrophy: major variations in practice. Muscle Nerve 48(1):27\u201331","journal-title":"Muscle Nerve"},{"issue":"20","key":"256_CR17","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1212\/WNL.0000000000003217","volume":"87","author":"RC Griggs","year":"2016","unstructured":"Griggs RC, Miller JP, Greenberg CR, Fehlings DL, Pestronk A, Mendell JR, Moxley RT 3rd, King W, Kissel JT, Cwik V, Vanasse M, Florence JM, Pandya S, Dubow JS, Meyer JM (2016) Efficacy and safety of deflazacort vs prednisone and placebo for Duchenne muscular dystrophy. Neurology 87(20):2123\u20132131","journal-title":"Neurology"},{"issue":"1","key":"256_CR18","doi-asserted-by":"publisher","first-page":"e201800186","DOI":"10.26508\/lsa.201800186","volume":"2","author":"CR Heier","year":"2019","unstructured":"Heier CR, Yu Q, Fiorillo AA, Tully CB, Tucker A, Mazala DA, Uaesoontrachoon K, Srinivassane S, Damsker JM, Hoffman EP, Nagaraju K, Spurney CF (2019) Vamorolone targets dual nuclear receptors to treat inflammation and dystrophic cardiomyopathy. Life Sci Alliance 2(1):e201800186","journal-title":"Life Sci Alliance"},{"key":"256_CR19","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/0092-8674(87)90579-4","volume":"51","author":"EP Hoffman","year":"1987","unstructured":"Hoffman EP, Brown RH, Kunkel LM (1987) Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 51:919\u2013928","journal-title":"Cell"},{"key":"256_CR20","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1056\/NEJM198805263182104","volume":"318","author":"EP Hoffman","year":"1988","unstructured":"Hoffman EP, Fischbeck KH, Brown RH, Johnson M, Medori R, Loike JD, Harris JB, Waterston R, Brooke M, Specht L, Kupsky W, Chamberlain J, Caskey CT, Shapiro F, Kunkel LM (1988) Dystrophin characterization in muscle biopsies from Duchenne and Becker muscular dystrophy patients. New Eng J Med 318:1363\u20131368","journal-title":"New Eng J Med"},{"key":"256_CR21","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1212\/WNL.39.8.1011","volume":"39","author":"EP Hoffman","year":"1989","unstructured":"Hoffman EP, Kunkel LM, Angelini C, Clarke A, Johnson M, Harris JB (1989) Improved diagnosis of Becker muscular dystrophy by dystrophin testing. Neurology 39:1011\u20131017","journal-title":"Neurology"},{"issue":"5","key":"256_CR22","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1212\/WNL.42.5.967","volume":"42","author":"EP Hoffman","year":"1992","unstructured":"Hoffman EP, Arahata K, Minetti C, Bonilla E, Rowland LP (1992) Dystrophinopathy in isolated cases of myopathy in females. Neurology 42(5):967\u2013975","journal-title":"Neurology"},{"key":"256_CR23","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.steroids.2018.02.010","volume":"134","author":"EP Hoffman","year":"2018","unstructured":"Hoffman EP, Riddle V, Siegler MA, Dickerson D, Backonja M, Kramer WG, Nagaraju K, Gordish-Dressman H, Damsker JM, McCall JM (2018) Phase 1 trial of vamorolone, a first-in-class steroid, shows improvements in side effects via biomarkers bridged to clinical outcomes. Steroids 134:43\u201352","journal-title":"Steroids"},{"key":"256_CR24","doi-asserted-by":"crossref","unstructured":"Hoffman EP, Schwartz BD, Mengle-Gaw LJ, Smith EC, Castro D, Mah JK, McDonald CM, Kuntz NL, Finkel RS, Guglieri M, Bushby K, Tulinius M, Nevo Y, Ryan MM, Webster R, Smith AL, Morgenroth LP, Arrieta A, Shimony M, Siener C, Jaros M, Shale P, McCall JM, Nagaraju K, van den Anker J, Conklin LS, Cnaan A, Gordish-Dressman H, Damsker JM, Clemens PR, The Cooperative International Neuromuscular Research Group (2019) Vamorolone trial in Duchenne muscular dystrophy shows dose-related improvement of muscle function. Neurology, in press","DOI":"10.1212\/WNL.0000000000008168"},{"issue":"1","key":"256_CR25","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1038\/s41467-018-03780-1","volume":"9","author":"WH Hudson","year":"2018","unstructured":"Hudson WH, Vera IMS, Nwachukwu JC, Weikum ER, Herbst AG, Yang Q, Bain DL, Nettles KW, Kojetin DJ, Ortlund EA (2018) Cryptic glucocorticoid receptor-binding sites pervade genomic NF-\u03baB response elements. Nat Commun 9(1):1337","journal-title":"Nat Commun"},{"key":"256_CR26","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1001\/jamaneurol.2019.0242","volume":"76","author":"S Joseph","year":"2019","unstructured":"Joseph S, Wang C, Bushby K, Guglieri M, Horrocks I, Straub V, Ahmed SF, Wong SC (2019) Fractures and linear growth in a nationwide cohort of boys with Duchenne muscular dystrophy with and without glucocorticoid treatment: results from the UK NorthStar database. JAMA Neurol 76:701. \n                https:\/\/doi.org\/10.1001\/jamaneurol.2019.0242","journal-title":"JAMA Neurol"},{"issue":"5","key":"256_CR27","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1002\/humu.20722","volume":"29","author":"A Kesari","year":"2008","unstructured":"Kesari A, Pirra LN, Bremadesam L, McIntyre O, Gordon E, Dubrovsky AL, Viswanathan V, Hoffman EP (2008) Integrated DNA, cDNA, and protein studies in Becker muscular dystrophy show high exception to the reading frame rule. Hum Mutat 29(5):728\u2013737","journal-title":"Hum Mutat"},{"key":"256_CR28","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/0092-8674(87)90504-6","volume":"50","author":"M Koenig","year":"1987","unstructured":"Koenig M, Hoffman EP, Bertelson CJ, Monaco AP, Feener C, Kunkel LM (1987) Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals. Cell 50:509\u2013517","journal-title":"Cell"},{"issue":"437","key":"256_CR29","doi-asserted-by":"publisher","first-page":"eaan0713","DOI":"10.1126\/scitranslmed.aan0713","volume":"10","author":"H Komaki","year":"2018","unstructured":"Komaki H, Nagata T, Saito T, Masuda S, Takeshita E, Sasaki M, Tachimori H, Nakamura H, Aoki Y, Takeda S (2018) Systemic administration of the antisense oligonucleotide NS-065\/NCNP-01 for skipping of exon 53 in patients with Duchenne muscular dystrophy. Sci Transl Med 10(437):eaan0713","journal-title":"Sci Transl Med"},{"issue":"1","key":"256_CR30","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.pmr.2011.11.014","volume":"23","author":"JN Kornegay","year":"2012","unstructured":"Kornegay JN, Childers MK, Bogan DJ, Bogan JR, Nghiem P, Wang J, Fan Z, Howard JF Jr, Schatzberg SJ, Dow JL, Grange RW, Styner MA, Hoffman EP, Wagner KR (2012) The paradox of muscle hypertrophy in muscular dystrophy. Phys Med Rehabil Clin N Am 23(1):149\u2013172","journal-title":"Phys Med Rehabil Clin N Am"},{"issue":"3","key":"256_CR31","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1212\/WNL.0000000000003504","volume":"88","author":"S Lefter","year":"2017","unstructured":"Lefter S, Hardiman O, Ryan AM (2017) A population-based epidemiologic study of adult neuromuscular disease in the Republic of Ireland. Neurology 88(3):304\u2013313","journal-title":"Neurology"},{"issue":"10119","key":"256_CR32","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/S0140-6736(17)32160-8","volume":"391","author":"CM McDonald","year":"2018","unstructured":"McDonald CM, Henricson EK, Abresch RT, Duong T, Joyce NC, Hu F, Clemens PR, Hoffman EP, Cnaan A, Gordish-Dressman H, Investigators CINRG (2018) Long-term effects of glucocorticoids on function, quality of life, and survival in patients with Duchenne muscular dystrophy: a prospective cohort study. Lancet 391(10119):451\u2013461","journal-title":"Lancet"},{"issue":"5","key":"256_CR33","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1016\/j.ajpath.2013.07.013","volume":"183","author":"PP Nghiem","year":"2013","unstructured":"Nghiem PP, Hoffman EP, Mittal P, Brown KJ, Schatzberg SJ, Ghimbovschi S, Wang Z, Kornegay JN (2013) Sparing of the dystrophin-deficient cranial sartorius muscle is associated with classical and novel hypertrophy pathways in GRMD dogs. Am J Pathol 183(5):1411\u20131424","journal-title":"Am J Pathol"},{"issue":"10","key":"256_CR34","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1080\/14740338.2018.1524868","volume":"17","author":"KD Nguyen","year":"2018","unstructured":"Nguyen KD, Bagheri B, Bagheri H (2018) Drug-induced bone loss: a major safety concern in Europe. Expert Opin Drug Saf 17(10):1005\u20131014","journal-title":"Expert Opin Drug Saf"},{"issue":"4","key":"256_CR35","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1212\/WNL.45.4.677","volume":"45","author":"E Pegoraro","year":"1995","unstructured":"Pegoraro E, Schimke RN, Garcia C, Stern H, Cadaldini M, Angelini C, Barbosa E, Carroll J, Marks WA, Neville HE, Marks H, Appleton S, Toriello H, Wessel HB, Donnelly J, Bernes SM, Taber JW, Weiss L, Hoffman EP (1995) Genetic and biochemical normalization in female carriers of Duchenne muscular dystrophy: evidence for failure of dystrophin production in dystrophin-competent myonuclei. Neurology 45(4):677\u2013690","journal-title":"Neurology"},{"issue":"11","key":"256_CR36","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1038\/nm.4234","volume":"22","author":"Railroading at the FDA","year":"2016","unstructured":"Railroading at the FDA (2016) Nat Med 22(11):1193. \n                https:\/\/doi.org\/10.1038\/nm.4234","journal-title":"Nat Med"},{"issue":"2","key":"256_CR37","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/S1474-4422(14)70318-7","volume":"14","author":"SV Raman","year":"2015","unstructured":"Raman SV, Hor KN, Mazur W, Halnon NJ, Kissel JT, He X, Tran T, Smart S, McCarthy B, Taylor MD, Jefferies JL, Rafael-Fortney JA, Lowe J, Roble SL, Cripe LH (2015) Eplerenone for early cardiomyopathy in Duchenne muscular dystrophy: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 14(2):153\u2013161","journal-title":"Lancet Neurol"},{"issue":"9","key":"256_CR38","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1080\/13696998.2018.1474750","volume":"21","author":"JB Rice","year":"2018","unstructured":"Rice JB, White AG, Johnson M, Wagh A, Qin Y, Bartels-Peculis L, Ciepielewska G, Nelson WW (2018a) Healthcare resource use and cost associated with varying dosages of extended corticosteroid exposure in a US population. J Med Econ 21(9):846\u2013852","journal-title":"J Med Econ"},{"issue":"8","key":"256_CR39","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1080\/03007995.2018.1474090","volume":"34","author":"JB Rice","year":"2018","unstructured":"Rice JB, White AG, Johnson M, Wagh A, Qin Y, Bartels-Peculis L, Ciepielewska G, Nelson WW (2018b) Quantitative characterization of the relationship between levels of extended corticosteroid use and related adverse events in a US population. Curr Med Res Opin 34(8):1519\u20131527","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"256_CR40","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13395-017-0141-y","volume":"7","author":"M St Andre","year":"2017","unstructured":"St Andre M, Johnson M, Bansal PN, Wellen J, Robertson A, Opsahl A, Burch PM, Bialek P, Morris C, Owens J (2017) A mouse anti-myostatin antibody increases muscle mass and improves muscle strength and contractility in the mdx mouse model of Duchenne muscular dystrophy and its humanized equivalent, domagrozumab (PF-06252616), increases muscle volume in cynomolgus monkeys. Skelet Muscle 7(1):25","journal-title":"Skelet Muscle"},{"issue":"8","key":"256_CR41","doi-asserted-by":"publisher","first-page":"e866","DOI":"10.1212\/WNL.0000000000006950","volume":"92","author":"M Taylor","year":"2019","unstructured":"Taylor M, Jefferies J, Byrne B, Lima J, Ambale-Venkatesh B, Ostovaneh MR, Makkar R, Goldstein B, Smith RR, Fudge J, Malliaras K, Fedor B, Rudy J, Pogoda JM, Marb\u00e1n L, Ascheim DD, Marb\u00e1n E, Victor RG (2019) Cardiac and skeletal muscle effects in the randomized HOPE-Duchenne trial. Neurology 92(8):e866\u2013e878","journal-title":"Neurology"},{"issue":"7","key":"256_CR42","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1136\/jnnp-2013-306350","volume":"85","author":"JC van den Bergen","year":"2014","unstructured":"van den Bergen JC, Wokke BH, Janson AA, van Duinen SG, Hulsker MA, Ginjaar HB, van Deutekom JC, Aartsma-Rus A, Kan HE, Verschuuren JJ (2014) Dystrophin levels and clinical severity in Becker muscular dystrophy patients. J Neurol Neurosurg Psychiatry 85(7):747\u2013753","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"256_CR43","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.omtn.2018.09.017","volume":"13","author":"N Watanabe","year":"2018","unstructured":"Watanabe N, Nagata T, Satou Y, Masuda S, Saito T, Kitagawa H, Komaki H, Takagaki K, Takeda S (2018) NS-065\/NCNP-01: an antisense oligonucleotide for potential treatment of exon 53 skipping in Duchenne muscular dystrophy. Mol Ther Nucl Acids 13:442\u2013449","journal-title":"Mol Ther Nucl Acids"},{"key":"256_CR44","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.jpeds.2016.11.078","volume":"182","author":"BL Wong","year":"2017","unstructured":"Wong BL, Rybalsky I, Shellenbarger KC, Tian C, McMahon MA, Rutter MM, Sawnani H, Jefferies JL (2017) Long-term outcome of interdisciplinary management of patients with Duchenne muscular dystrophy receiving daily glucocorticoid treatment. J Pediatr 182:296\u2013303","journal-title":"J Pediatr"}],"container-title":["Handbook of Experimental Pharmacology","Pediatric Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/164_2019_256","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,4]],"date-time":"2020-08-04T00:02:58Z","timestamp":1596499378000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/164_2019_256"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"ISBN":["9783030504939","9783030504946"],"references-count":43,"URL":"https:\/\/doi.org\/10.1007\/164_2019_256","relation":{},"ISSN":["0171-2004","1865-0325"],"issn-type":[{"type":"print","value":"0171-2004"},{"type":"electronic","value":"1865-0325"}],"subject":[],"published":{"date-parts":[[2019]]},"assertion":[{"value":"3 August 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}